Shots:

• Roche has signed a purchase agreement to acquire 100% of the outstanding shares of the TIB. The transaction is expected to close in Q4’21
• The acquisition will bolster Roche’s PCR test portfolio of molecular diagnostics solutions with the addition of multiple assays for infectious disease
• TIB Molbiol currently has 45+ CE-IVD marked tests and 100+ research use assays that are available on Roche's LightCycler PCR and MagNA Pure sample preparation systems

Ref: Globe Newswire | Image: Roche